Abstract
Background In Rwanda, epidemiological data characterizing people who inject drugs (PWID) and their burden of HIV are limited. We examined injecting drug use (IDU) history, practices, and HIV infection in a sample of PWID in Kigali.
Methods From October 2019–February 2020, 322 PWID aged ≥18 were enrolled in a cross-sectional study using convenience sampling in Kigali. Participants underwent a structured interview and HIV testing. We used Poisson regression with robust variance estimation to assess IDU practices associated with HIV infection.
Results The median age was 28 years(IQR:24-31) and 81%(248) were male. The median age at first injection was 23 years (IQR:20-27). HIV prevalence was 9.5%(95%CI:8.7-9.3).
In the six months preceding the study, heroin was the primary drug of choice for 99%(303); but cocaine and methamphetamine were also reported by 10%(31) and 4%(12) respectively. Furthermore, 31%(94) and 33%(103) of participants, shared or reused needles in the previous six months, respectively. Up to 43%(133) knew someone who died from a drug-related overdose. PWID reporting sharing needles at least half the time in the previous six months had increased likelihood of HIV-infection, compared to those who did not (aPR: 2.67; 95%CI:1.23–5.78).
Conclusion HIV infection was common in this sample of PWID in Kigali. The high prevalence of needle reuse and sharing practices highlight significant risk for onward transmission and acquisition of HIV and hepatitis B and C. PWID-focused harm reduction services, including needle and syringe programs, safer injection education, naloxone distribution, and substance use disorder treatment programs, are needed in Rwanda.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was internally funded by HDI resources. CB is supported in part by the Desmond M. Tutu Professorship at Johns Hopkins University. NPM is supported through T32 NRSA Pre-doctoral Training Fellowship in HIV Epidemiology and Prevention Sciences (5T32AI102623-08) within the Johns Hopkins University Center for Public Health and Human Rights. SB is supported in part by a grant from the National Institutes of Mental Health (R01MH110358).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Rwanda National Ethics Committee N: 027/RNEC/2020
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email Addresses of Authors Jean Olivier Twahirwa Rwema: jtwahir1{at}jhmi.edu
Vianney Nizeyimana: dvianney{at}hdirwanda.org
Neia Prata Menezes: npratam1{at}jhmi.edu
Nneoma E. Okonkwo: nneoma{at}jhmi.edu
Athanase Rukundo: athanase{at}hdirwanda.org
Amelia Aibina Mazzei: amazze2{at}emory.edu
Sulemani Muhirwa: muhisule{at}hdirwanda.org
Lisa Lucas: llucas11{at}jhmi.edu
Audace Niyigena: audace.niyigena{at}hcuge.ch
Jean Damascène Makuza: makorofr{at}gmail.com
Chris Beyrer: cbeyrer{at}jhu.edu
Stefan Baral: sbaral{at}jhu.edu
Aflodis Kagaba: kagaba{at}hdirwanda.org
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.